EDARADD抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P02152(EDARADD Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The EDARADD (EDAR-associated death domain) antibody is a crucial tool for studying the EDARADD protein, a key component in the ectodysplasin signaling pathway. EDARADD acts as an adaptor molecule that mediates interactions between the EDAR (Ectodysplasin A receptor) and downstream signaling proteins, particularly through its death domain, which facilitates the activation of NF-κB and other pathways. This pathway is essential for regulating ectodermal development, including hair follicle formation, tooth morphogenesis, and sweat gland differentiation. Mutations in the EDARADD gene are linked to hypohidrotic ectodermal dysplasia (HED), a genetic disorder characterized by abnormal development of skin, hair, teeth, and glands.

EDARADD antibodies are widely used in research to detect and quantify the protein’s expression in tissues and cell lines via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). They help elucidate EDARADD’s role in developmental biology, disease mechanisms, and its interplay with other signaling molecules (e.g., TRAF6). Additionally, these antibodies contribute to studies exploring potential therapeutic targets for HED or cancers where ectodysplasin signaling is dysregulated. Commercial EDARADD antibodies are typically validated for specificity and sensitivity, often targeting conserved regions of the protein across species. Researchers rely on these tools to advance understanding of ectodermal morphogenesis and related pathologies.